Pathophysiology of Diabetic Dyslipidemia
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Accumulating clinical evidence has suggested serum triglyceride (TG) is a leading predictor of atherosclerotic cardiovascular disease, comparable to low-density lipoprotein (LDL)-cholesterol (C) in populations with type 2 diabetes, which exceeds the predictive power of hemoglobinA1c. Atherogenic dyslipidemia in diabetes consists of elevated serum concentrations of TG-rich lipoproteins (TRLs), a high prevalence of small dense low-density lipoprotein (LDL), and low concentrations of cholesterol-rich high-density lipoprotein (HDL)2-C. A central lipoprotein abnormality is an increase in large TG-rich very-low-density lipoprotein (VLDL)1, and other lipoprotein abnormalities are metabolically linked to increased TRLs. Insulin critically regulates serum VLDL concentrations by suppressing hepatic VLDL production and stimulating VLDL removal by activation of lipoprotein lipase. It is still debated whether hyperinsulinemia compensatory for insulin resistance is causally associated with the overproduction of VLDL. This review introduces experimental and clinical observations revealing that insulin resistance, but not hyperinsulinemia stimulates hepatic VLDL production. LDL and HDL consist of heterogeneous particles with different size and density. Cholesterol-depleted small dense LDL and cholesterol-rich HDL2 subspecies are particularly affected by insulin resistance and can be named "Metabolic LDL and HDL," respectively. We established the direct assays for quantifying small dense LDL-C and small dense HDL(HDL3)-C, respectively. Subtracting HDL3-C from HDL-C gives HDL2-C. I will explain clinical relevance of measurements of LDL and HDL subspecies determined by our assays. Diabetic kidney disease (DKD) substantially worsens plasma lipid profile thereby potentiated atherogenic risk. Finally, I briefly overview pathophysiology of dyslipidemia associated with DKD, which has not been so much taken up by other review articles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the activation of PPARα reduces small dense LDL particles by (1) producing apo C-III-poor VLDL particles that interacts less well CETP and (2) increasing the formation of large buoyant LDL that has a high affinity to and are easily taken up by LDL receptor.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-elevated LDL cholesterol values together with higher triglycerides and lower HDL-cholesterol are common in patients with abdominal obesity, T2D, and metabolic syndrome (61, 62); these individuals often still have elevated atherogenic lipoproteins such as non-HDL (63), small LDL particles (62, 64), and VLDL (62, 64).”
From Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial (2019) · cites this paper as [64]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cholesterol accumulation in the brain, particularly in astrocytes, contributes to this pathological process.”
From Cholesterol-driven pathological astrocytic responses in diabetes-associated cognitive impairment through astrocytic SCAP accumulation and NF-κB–C3 signaling modulation (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411
Lewis, G. F., Carpentier, A., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,333
Stampfer, M. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110036029 · Cited by 1,079
Cited by
Items 301–400 of 552
Nguyen, S. V., Nguyen, H.-D., Dang, V. V., Doan, B. D., Dinh, B. Q., Nguyen, T. T., Nguyen, C. Q., & Pham, D. T. M. (2024) · Biomedical Research and Therapy · doi:10.15419/bmrat.v11i4.876 · Cited by 2
“Given the atherogenic lipid profile commonly seen in diabetic patients—marked by prominent hypertriglyceridemia 12 —fibrates’ efficacy in reducing triglycerides does not translate well to lowering LDL cholesterol.”
Jawad, A. N., Kadhim, K. A., Alzajaji, Q. B., & Al-Neshmi, H. (2024) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v24i3.1082 · Cited by 2
Predictive markers of early endothelial dysregulation in type-1 diabetes: a meta-analysis
Ranasinghe, R., Mathai, M. L., Alshawsh, M. A., & Zulli, A. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02401-2 · Cited by 3
“It is an imbalance between the favourable and the unfavourable cholesterol with the low-density lipoprotein cholesterol (LDL-c) being more than the high-density lipoprotein cholesterol (HDL-c) [ 25].”
Potential antihyperlipidemic effects of myrcenol and curzerene in high-fat fed rats
Tahir, S., Abdo, A., Mobashar, A., Shabbir, A., Najam, K., Ibrahim, A., Hussain, K., Jardan, Y. A. B., Ibenmoussa, S., & Younous, Y. A. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00838-x · Cited by 2
Wickramasinghe, A. S. D., Attanayake, A. P., Kalansuriya, P., & Menuka, L. D. A. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402965 · Cited by 2
Ibrahim, N. ‘., Tadj, N. B. M. I., Leong, S. M., Sabaruddin, M. H., Heberd, N. F. A., Razali, N. I. S., Nagalingam, T., Saad, Q. H. M., Sidik, T. M. I. T. A. B., Leow, S.-S., et al. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.106810 · Cited by 2
Razali, N. I., Widyawati, T., Anggraini, D. R., Lim, V., & Yusoff, N. A. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-04933-8 · Cited by 5
“Dys-lipidemia in diabetes is common irrespective of insulin deficiency or insulin resistance [25].”
Pan, D., Chen, P., Ji, S.-Y., Chen, T., & Zhang, H. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.101434 · Cited by 3
“Studies have shown that patients with diabetes have lipid metabolism dysfunction, characterized by elevated non-HDL-C and reduced HDL-C levels even in patients with well-controlled glucose levels[21,22].”
Association between AIP and incident T2DM in patients with NAFLD: a retrospective study
Chen, Y., Bai, Q., & Hua, H. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02046-4 · Cited by 3
“This dyslipidemic state is closely linked to insulin resistance, as excessive TG-rich lipoproteins interfere with insulin signaling pathways in peripheral tissues, including skeletal muscle and adipose tissue [28, 29].”
Patterns of lipid profile and genetic variations in South Asians
Rahmanian, M. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00246-4 · Cited by 5
“The insulin resistance and hyperglycemia associated with diabetes mellitus impair the lipolysis of triglycerides and LDL uptake [26].”
Sabadashka, M., Chala, D., Chrzanowski, G., Cichoński, J., & Sybirna, N. O. (2025) · Molecules · doi:10.3390/molecules30214183 · Cited by 3
“It represents an important metabolic consequence of the disease and may appear long before hyperglycemia develops in patients with diabetes [36,37].”
Mochu, M. U., Osias, K., Nnorom, F. I., Fakoya, O., Adebayo, A. A., Nathan-Otu, E., & Emanemua, C. E. (2025) · Cureus · doi:10.7759/cureus.96124 · Cited by 2
“These findings are consistent with prior studies showing that aging and obesity exacerbate lipid abnormalities in diabetes through metabolic and hormonal pathways [4,7,14].”
Wu, J., Lin, Y. M., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M. H., Yu, T., & Lai, C.-C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1709009 · Cited by 3
“This risk is further exacerbated in individuals who have concomitant dyslipidemia (5, 6).”
Lipid metabolism in type 1 and type 2 diabetes: A comparative cross-sectional study
Saleh, F. B., Alibrahim, A. R., Alshahrani, A. S., Aldughaither, A., Mahzari, M. M., Alharbi, W. S., & Alanazi, G. B. (2025) · Medicine · doi:10.1097/md.0000000000046758 · Cited by 2
“[29] Given the elevated LDL levels in patients with T1DM, more aggressive lipid-lowering therapies may be required to reduce cardiovascular risk.”
Darwich, N. A., Abouzeinab, N. S., El-Sayed, A., Hajj, R. E., & Khalil, M. I. M. (2026) · BioMed Research International · doi:10.1155/bmri/1938383 · Cited by 2
“These fi ndings accord well with previous studies showing the anti-in fl ammatory and antioxidant e ff ects of green-synthesized NPs, resulting in reduced cellular damage, in fl ammation, and necrosis [46, 47].”
He, Z., Diao, J., Hamel, F. G., & Duan, B. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.02.023 · Cited by 4
“DPN occurs due to hyperglycemia, hyperlipidemia, and dysregulated insulin metabolism [9,10].”
Current evidence on lipid ratios for cardiovascular risk assessment in diabetes: A review
Carretero-Anibarro, E., & Orozco‐Beltrán, D. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.02.008 · Cited by 2
Mangoni, A. A., Hulin, J.-A., & Tommasi, S. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100147 · Cited by 2
Duan, Y., Gao, H., Su, H., Liu, A., Liu, Y., Yuan, H., & Xie, C. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200225094756 · Cited by 2
Dwiyanti, H., Setyawati, R., Prihananto, V., & Krisnansari, D. (2021) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/653/1/012147 · Cited by 2
Redox index of Cys-thiol residues of serum apolipoprotein E and its diagnostic potential
Yamauchi, K., Taira, C., & Kawakami, Y. (2021) · Bioscience Reports · doi:10.1042/bsr20211060 · Cited by 4
“Subsequently, the remnants are rapidly removed from circulation via receptor-mediated clearance [24,28].”
InfluentialBarre, D. E., & Mizier-Barre, K. A. (2021) · Endocrine Regulations · doi:10.2478/enr-2021-0020 · Cited by 2
“(1973a); elevated triglycerides can be a problem as they increase atherosclerotic risk (Hsueh and Law 1998) in PT2D and T2D due to such elevation causing decreased increased sd-LDLc (Nikolic et al. 2013; Hirano 2018) and decreased HDLc (Calabresi et al.”
BackgroundPark, T., Han, K., Shin, D. W., & Park, J.-H. (2022) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2022.4.e15 · Cited by 2
“As of the index date, T2D patients who had not received a medical examination during the previous 2 years and within 2 years thereafter were excluded.”
BackgroundInfluentialSitepu, A. N. R., Lindarto, D., & Nasution, M. S. (2023) · Journal of Society Medicine · doi:10.47353/jsocmed.v2i3.37 · Cited by 2
Elevation in white blood cell count and development of hyper LDL cholesterolemia
Okutsu, S., Kato, Y., Takeoka, H., Funakoshi, S., Maeda, T., Yoshimura, C., Kawazoe, M., Satoh, A., Tada, K., Takahashi, K., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-35436-6 · Cited by 2
Melakhessou, M. A., Becheker, I., Marref, S. E., Bensaad, M. S., Alyamani, A. A., Sami, R., Helal, M. M. K., Aljaadi, A. M., Al-Eisa, R. A., Algehainy, N. A., et al. (2023) · Journal of Biobased Materials and Bioenergy · doi:10.1166/jbmb.2023.2288 · Cited by 3
Choi, H., & Kim, J.-I. (2024) · Nutrition Research and Practice · doi:10.4162/nrp.2024.18.1.88 · Cited by 2
“Increase in TG-rich VLDL in blood circulation is considered a risk factor for diabetic atherogenic dyslipidemia [2,11].”
BackgroundInfluence of triglyceride concentration in lipoprotein(a) as a function of dyslipidemia
Marco-Benedí, V., Cenarro, A., Laclaustra, M., Calmarza, P., Bea, A. M., Vila, À., Morillas, C., Puzo, J., García, J. D. M., Alamán, A. I. F., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.03.001 · Cited by 6
Mohyeldin, S. M., Daabees, H. G., Talaat, W., & Kamal, M. F. (2024) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2024.101777 · Cited by 2
Rao, B. M., Vedavijaya, T., Ramani, Y. R., & Sayana, S. B. (2025) · Cureus · doi:10.7759/cureus.77420 · Cited by 4
“Dyslipidemia in diabetes results from elevated levels of unbound fatty acids, which promote the enhanced synthesis of triglycerides and VLDL, along with reduced HDL levels, thus enhancing the risk of cardiovascular diseases [13-15].”
Dyslipidaemia in Liver Diseases
Hlušička, J., & Žák, A. (2024) · Folia Biologica · doi:10.14712/fb2024070050239 · Cited by 2
Li, C., Qiao, L., & Tang, L. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02043-7 · Cited by 4
“Furthermore, insulin resistance can increase the production of very low-density lipoprotein (VLDL) and LDL in the liver while simultaneously inhibiting LDL receptor (LDL-R) expression, thus disrupting normal lipid metabolism [40, 41].”
Pan, J., Yang, X., & Zhu, W. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00768-9 · Cited by 2
Bağır, G. Ş., Bakıner, O., Haydardedeoğlu, F. E., Araz, F., Ertörer, M. E., & Kozanoğlu, İ. (2020) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13603 · Cited by 2
Tursinawati, Y., Kartikadewi, A., Yuniastuti, A., & Susanti, R. (2021) · Advances in health sciences research/Advances in Health Sciences Research · doi:10.2991/ahsr.k.210115.029 · Cited by 3
Menambath, D. T., Yalla, D. R., Ashok Prabhu, K., Kuthethur, S., & Mangalore, N. (2021) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v13i2.1312 · Cited by 2
Pastukhova, Y., Luzza, F., Shevel, S., Savchuk, О., Остапченко, Л. І., Falalyeyeva, T. M., Molochek, N., Кuryk, О. G., Korotkyi, O., & Kobyliak, N. M. (2022) · Reviews on Recent Clinical Trials · doi:10.2174/1574887117666220321152855 · Cited by 2
Diabetes Aggravates Photoreceptor Pathologies in a Mouse Model for Ocular Vitamin A Deficiency
Ramkumar, S., Parmar, V. M., Moon, J., Lee, C., Taylor, P. R., & Lintig, J. V. (2022) · Antioxidants · doi:10.3390/antiox11061142 · Cited by 3
“The elevated retinoid concentrations in the eyes of the diabetic Stra6-/- mice are likely explained by the effects of diabetes on lipoprotein metabolism [29].”
BackgroundProtective Effect of Mulberry Leaf and Yacon Extract Induced Hyperlipidemia in Obese Rats
Lim, Y., Oh, J. H., Park, U. K., Huh, M. K., & Hwang, S. (2020) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2020.26.2.101 · Cited by 3
“The inverse relationship between HMG-CoA reductase and LDL, appeared due to the reduction of LDL, and it was considered that cholesterol level of blood and liver tissue is decreased due to the negative feedback of HMG-CoA reductase (Choi and Lee, 1992; Hirano, 2018).”
Hirschstein, Z., Wang, A., Anderson, B. M., Novakovic, Z. M., & Grasso, P. (2021) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-020-10155-y · Cited by 2
“2016; Hirano 2018;).”
Роль дисліпідемії в розвитку нефропатії у хворих на цукровий діабет 2-го типу (огляд літератури)
Ismailov, S. I., & Muminova, S. (2020) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.8.2019.191689 · Cited by 2
Mahdavifard, S., & Nakhjavani, M. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00967-0 · Cited by 1
Mirshekari, M., Zargaran, A., Shirzad, N., Hemmatabadi, M., Khanavi, M., Ebrahimpur, M., Afra, F., & Namazi, S. (2022) · Pharmaceutical Sciences · doi:10.34172/ps.2022.36 · Cited by 1
Masuda, Y., Kishimoto, N., Yamada, C., Akira, K. U. B. O., Moriyama, K., Suzuki, N., Akina, M. I. N. E., Okuno, C., Takashimizu, S., & Nishizaki, Y. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0034 · Cited by 1
“11 In addition, it has been reported that the HDL2-C/HDL3-C ratio was associated with lipid metabolism.”
Adropin, Insulin, Insulin Resistance and Lipid Profile Levels in Diabetes Mellitus Type2 Patients
Ahmed, E. H., & Abdulwahed, A. M. H. (2023) · Aalborg Academy Journal of Medical Sciences · doi:10.32441/ijms.6.3.4 · Cited by 1
“This stimulates production of VLDL-C, which is necessary for the transport of these triglycerides[18].”
BackgroundAyodele, O. O., Onajobi, F. D., Okoro, E. E., & Osoniyi, O. R. (2023) · Pharmacognosy Research · doi:10.5530/pres.15.4.080 · Cited by 1
Etti, I. C., Essang, E.-O. A., & Olorunsola, E. O. (2024) · Asian Journal of Biochemistry Genetics and Molecular Biology · doi:10.9734/ajbgmb/2024/v16i6383 · Cited by 1
Risk factors for fasting blood glucose control in middle-aged and elderly type 2 diabetes patients
Kuang, N.-Y., Ye, H., Chen, J.-P., Li, H., & Tang, N. (2024) · Medicine · doi:10.1097/md.0000000000039322 · Cited by 2
“[32] Several studies have indicated [33,34] that common blood lipid abnormalities in patients with T2DM mainly include abnormal levels of TG and HDL-C; elevated TG and low HDL-C levels can lead to insulin resistance, resulting in poor blood glucose control and forming a vicious cycle.”
BackgroundChalie, S., Ewunetie, A. A., Assemie, M. A., Birhanie, A. L., Molla, F., Telayneh, A. T., & Endalew, B. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01695-1 · Cited by 2
“This might be due to high levels of triglycerides in the blood are a common problem for people with diabetes and these levels simply rise with increasing blood sugar, they are actually more closely linked to insulin resistance and the body’s overproduction of insulin [48].”
BackgroundGu, W., Wang, Z., Wu, G., Guo, H., Cheng, H., Li, C., Chen, L., Li, D., & Xie, Z. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250271 · Cited by 1
Oguekwe, O., Oguwike, F., Nwozor, C., & Odikpo, N. (2024) · Greener Journal of Biomedical and Health Sciences · doi:10.15580/gjbhs.2024.1.060624073 · Cited by 1
“However, it is characterized by hypertriglyceridemia, reduced HDL cholesterol levels, and an increased concentration of Low-Density-Lipoprotein particles (Daya et al., 2017; Hirano, 2018).”
Mayer, F., Innerhofer, R., Köller, T., & Binder, C. J. (2024) · Learning materials in biosciences · doi:10.1007/978-3-031-64591-4_10 · Cited by 1
Kumari, N., Shamkuwar, C. A., Motghare, V. M., & Dakhale, G. N. (2025) · Cureus · doi:10.7759/cureus.85457 · Cited by 3
“Statins are commonly prescribed to treat dyslipidemia in patients with T2DM, aiding beneficiaries in both primary and secondary prevention of CVD [36,37].”
Zafrah, H. A., Amri, F. S. A., Alqahtani, S. A., Almasabi, F., Shati, A. A., Dawood, A. F., ShamsEldeen, A. M., Al‐Ani, B., Alharbi, R., & Kamar, S. S. (2025) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-025-00265-8 · Cited by 1
“Additionally, Insulin resistance is associated with lipid and lipoprotein metabolism abnormalities, contributing to the development of steatohepatitis [7, 8].”
Aduol, K. O., Onyango, A. N., Kiage, B. N., Okoth, J. K., & Ayua, E. (2025) · Journal of Food Science · doi:10.1111/1750-3841.70555 · Cited by 6
Nemukula, M., Mkhwanazi, S., Mapheto, T. J., Malaisamy, A., Bhavesh, N. S., Majane, O. H. I., & Gololo, S. S. (2025) · Obesities · doi:10.3390/obesities5040070 · Cited by 1
“Additionally, dyslipidemia in diabetes is characterized by raised fasting and postprandial triglycerides, low HDL-cholesterol (HDL-C), raised LDL-cholesterol (LDL-C), and the predominance of small dense LDL particles [7,8].”
Non-linear associations of a body shape index with diabetes among adults: A cross-sectional study
Chen, K., Tang, C., Li, Y., Zhu, D., Zhang, X., Cui, S., Zhu, Z., & Fang, F. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333883 · Cited by 1
Yin, H., Chen, W., He, X., & Zeng, J. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100437 · Cited by 1
Hu, Y., Yang, L., Yan, G., Sun, Y., Wang, M., Kong, L. D., Sun, H., Zhao, X., Zhang, X., HUANG, R., et al. (2026) · Chinese Medicine · doi:10.1186/s13020-025-01289-6 · Cited by 2
“This pattern is closely associated with IR: under IR conditions, excess FFA flood the liver, shifting metabolic focus from β-oxidation to TG synthesis and VLDL assembly, directly leading to high VLDL levels [70–72].”
Ilkhanipoor, H., far, N. T., Moravej, H., Barzegar, H., Salarian, L., Afshar, Z., & Nazari, A. (2026) · BMC Pediatrics · doi:10.1186/s12887-025-06504-9 · Cited by 1
“Additionally, hepatic de novo lipogenesis may further amplify VLDL production [28].”
Sellam, M., Lambert, M., Varin‐Blank, N., & Saitoski, K. (2026) · Metabolites · doi:10.3390/metabo16020145 · Cited by 1
“Dyslipidemia is also frequently observed as a secondary consequence of chronic conditions such as diabetes, renal dysfunction, and liver disease [47–49].”
Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes
Wahab, R. A., & Mahmood, W. A. W. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514261422310 · Cited by 2
“5,6 Insulin resistance in diabetes stimulates hormone-sensitive lipase, which releases free fatty acids from the adipose tissue (lipolysis) and increases hepatic triglycerides (Tg) and very low-density lipoprotein (VLDL) production.”
Xu, J., Zhu, S., Wang, T., & Lu, W. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1713324 · Cited by 1
Zeppieri, M., Drigo, A., Capobianco, M., Visalli, F., Cappellani, F., Musa, M., Giglio, R., Tognetto, D., Khouyyi, M., Gagliano, C., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i3.114603 · Cited by 1
Estimated small dense low-density lipoprotein cholesterol and hyperuricemia in diabetic patients
Xu, M., Yan, H., Xue, Y., Yin, Y., Shao, X., & Yang, Q. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1790201 · Cited by 1
Zhao, Y., Huang, W., Li, W., & Shi, Z. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05734-8 · Cited by 1
“VLDL1 is the precursor of sdLDL, and its catabolism forms cholesteryl ester-rich sdLDL particles [34, 35].”
Kim, P. S., Kang, M., Sang, H., Rhee, S. Y., & Lim, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1791174 · Cited by 1
“Simultaneously, the resulting triglyceride-rich environment promotes the exchange of triglycerides into HDL particles, making them susceptible to rapid catabolism and thereby lowering circulating HDL-cholesterol levels (34).”
Wang, R., Zhao, J., Tang, Y., Zhang, Q., Xie, D., Dong, W., & Li, X. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.108950 · Cited by 2
Rao, Z., Xu, C., Yu, Y., 朱根应, Liu, Y., Wen, X., Zhu, C., & Zhang, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1826387 · Cited by 1
“These ratio-based indices demonstrated stronger associations with functional outcome compared to isolated lipid concentrations, likely reflecting the critical balance between atherogenic burden and protective functions (10).”
Erol, A., & Şahin, M. F. (2026) · Biomedicines · doi:10.3390/biomedicines14091995 · Cited by 1
“Diabetic dyslipidemia is typically characterized by elevated triglyceride levels, reduced high-density lipoprotein cholesterol (HDL-C) levels, and qualitative changes in low-density lipoprotein cholesterol (LDL-C) particles [7–10].”
Petca, B.-L., Popovici, P.-A., Igna, A. D., Ghitea, T. C., & Popoviciu, M. S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187315 · Cited by 1
“Importantly, these pathological processes develop simultaneously rather than independently, supporting the concept of an integrated cardio–renal–metabolic continuum [4–6].”
Davids, S. F. G., Matsha, T. E., Peer, N., Erasmus, R. T., & Kengne, A. P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00753 · Cited by 1
“The distribution of cardiometabolic risk factors differed across BMI categories and obesity phenotype, which was similar to previous reports involving different population groups (26, 28, 29, 44, 47, 48).”
ResultAnti-obesity Effects of Mulberry Leaf and Yacon Extract in Obese Rats
Lim, Y., Oh, J. H., Park, U. K., Huh, M. K., & Hwang, S. (2020) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2020.26.2.75 · Cited by 1
Parmar Vinendra, M. (2020) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2020.13.555869 · Cited by 1
“4 No: 844 levels of NEFA also increase hepatic triglyceride production [5,6].”
BackgroundTanashyan, M. М., Антонова, К. В., Шабалина, А. А., Лагода, О. В., & Быковская, М. А. (2020) · Human Physiology · doi:10.1134/s0362119720080125 · Cited by 1
“The level of sdLDL increases in hypertriglyceridemia, the most common dyslipidaemia in patients with T2DM [13].”
BackgroundA rare presentation of type 1 diabetes mellitus
Ateko, O. A., Lawal, Y., Reng, R. S., Ugwuneji, U. O., Julius, I. U., & Anumah, F. E. (2022) · The Journal of Clinical and Scientific Research · doi:10.4103/jcsr.jcsr_44_21 · Cited by 1
(2019) · International Journal of Diabetes & Metabolic Disorders · doi:10.33140/ijdmd.04.06.09 · Cited by 1
Pradhyta, F. P., Sartika, R. A. D., & Sauriasari, R. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666221130104225 · Cited by 1
Diabetic rats: Hyperlipidemia and role of mango seed
Azhar, A., Asad, F., Rizvi, F., Abid, F., & Farooqui, M. U. (2023) · Journal of Clinical and Experimental Investigations · doi:10.29333/jcei/13213 · Cited by 1
Ito, R., Manita, D., Yanai, H., & Hirowatari, Y. (2023) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632231179082 · Cited by 1
Ahooghalandary, S. (2022) · مجله علمی پزشکی جندی شاپور · doi:10.32598/jsmj.21.5.2471 · Cited by 2
Elkurnia, R. T., Cokorde Istri Yuliandari Krisnawardani, K., Suastika, L. O. S., & Sinardja, C. W. D. (2023) · Intisari Sains Medis · doi:10.15562/ism.v14i1.1573 · Cited by 1
Sagñay-Novillo, A. F., Vermudez-Pirela, V. J., & Patricia-Elizabeth, V. I. (2024) · MQRInvestigar · doi:10.56048/mqr20225.8.1.2024.1343-1359
Ahmed, V. A., Rahman, H. S., Raheem, M. O. M., Othman, H. H., Algarawi, M., & Ibnaouf, K. H. (2024) · Natural Product Communications · doi:10.1177/1934578x241259377 · Cited by 1
“35 In diabetes, a reduction in lipoprotein lipase activity, an enzyme responsible for breaking down TG and VLDL, occurs due to insulin de fi ciency.”
CONNECTING THE DOTS: INVESTIGATING THE RELATIONSHIP BETWEEN HBA1C AND LIPID PROFILE
KI, J., K, S., Mohan Kumar, M., Aparnavi, P., & Shanmugam, J. (2024) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2024v17i12.50249 · Cited by 3
Shahria, N., Saifullah, M. K., Talukder, M. S., Sohag, M. S. U., Sohag, S. M., Khatun, M. F., Mahmud, I., Alam, A. H. M. K., Rahman, M. A. A., & Rashid, M. (2025) · Pharmacology & Pharmacy · doi:10.4236/pp.2025.165010 · Cited by 1
Huang, C., Zhang, Y., Yang, X., Li, G., & Gao, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1502861 · Cited by 1
Dyslipidemia in type 2 diabetes mellitus (T2dm): Pathophysiology, pattern and management
Karale, S., Dhanya, A. V., Varkey, P., Anil, A., & Abhijith, K. (2019) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2019.008 · Cited by 1
Is HbA1c level affected by high triglyceride levels?
Araç, E., & Solmaz, İ. (2020) · Ortadoğu Tıp Dergisi · doi:10.21601/ortadogutipdergisi.715645 · Cited by 1
“İnsülin karaciğerde lipoprotein lipaz (LpL) enzim aktivitesini düzenler ve apolipoprotein üretimini etkileyerek diyabetik dislipidemi gelişir [6,7].”
BackgroundExercício aquático e modulação autonômica cardíaca de mulheres na pós-menopausa com diabetes tipo 2
Chagas, E. F. B., da Cruz, A. C., Rodrigues, P. H., da Silva, C. S., & Quitério, R. J. (2021) · Revista Brasileira de Fisiologia do Exercício · doi:10.33233/rbfe.v19i2.3120 · Cited by 3
Arora, V., & Darshan, A. (2022) · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · doi:10.36106/ijsr/8206464 · Cited by 1
Chughtai, L. A., Zai, J. A., Mughal, Z. U.-N., & Faheem, B. (2018) · Journal of Liaquat University of Medical & Health Sciences · doi:10.22442/jlumhs.181740580 · Cited by 1
Correlation of advanced glycation end products and heme oxygenase-1 in Korean diabetic patients
Choi, H., Koo, D.-H., & Yim, J. (2022) · Journal of Nutrition and Health · doi:10.4163/jnh.2022.55.3.348 · Cited by 1
Heidari, M., Hajizadeh‐Sharafabad, F., & Alizadeh, M. (2022) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.09.004 · Cited by 1
Marinković, M., & Petrović, I. (2022) · EABR. Experimental and Applied Biomedical Research · doi:10.2478/sjecr-2022-0008 · Cited by 1
Profil Lipid Pada Pasien Diabetes Melitus Tipe 2 di RSUP Sanglah Denpasar Tahun 2019
Siorcani, P. T., Suastika, K., Gotera, W., & Dwipayana, I. M. P. (2022) · E-Jurnal Medika Udayana · doi:10.24843/mu.2022.v11.i01.p16 · Cited by 1
Loesch, D. P., Garg, M., Matelska, D., Vitsios, D., Jiang, X., Ritchie, S. C., Sun, B. B., Runz, H., Whelan, C. D., Holman, R. R., et al. (2024) · medRxiv · doi:10.1101/2024.03.15.24304200 · Cited by 1
Zhang, L., Niu, J.-J., He, X.-M., Zheng, X., Zhao, Q.-G., Yu, X.-J., Luo, L., Ren, H., & Pei, Y. (2024) · medRxiv · doi:10.1101/2024.04.16.24305933 · Cited by 1
Sharif, A., Mamo, J. C. L., Lam, V., Watts, G. F., Luna, G., Nesbit, M., Al‐Salami, H., Mooranian, A., & Takechi, R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.05.622070 · Cited by 1
Simkhada, S., Ghimire, S., Dhami, M., Karki, P., & Pandit, A. S. (2025) · medRxiv · doi:10.1101/2025.09.16.25335898 · Cited by 1
Metadata
- Authors
- Hirano, T.
- Affiliations
- SHOWA Medical University (JP)
- Corresponding author
- Hirano, Tsutomu
- ORCID
- Hirano, Tsutomu
- Venue
- Journal of Atherosclerosis and Thrombosis
- Publisher
- Japan Atherosclerosis Society
- Published
- 2018-09-01
- Volume
- 25
- Issue
- 9
- Pages
- 771-782
- ISSN
- 1340-3478 (ISSN-L)
- 1880-3873
- PMC
- PMC6143775
- OpenAlex
- W2820707192
- Cited by
- 552
- References
- 102
- Citations by year
- 2026: 65 · 2025: 90 · 2024: 81 · 2023: 86 · 2022: 88 · 2021: 70 · 2020: 46 · 2019: 21 · 2018: 4
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Atherosclerosis and Thrombosis (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- diabetic dyslipidemia, type 2 diabetes, triglyceride-rich lipoproteins, VLDL, small dense LDL, HDL2, HDL3 cholesterol, insulin resistance, hyperinsulinemia, lipoprotein lipase, atherosclerotic cardiovascular disease, diabetic nephropathy, plasma lipid profile
- MeSH terms
- Pioglitazone, Animals, Cholesterol, Chylomicrons, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fatty Acids, Nonesterified, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Lipoproteins, Cholesterol, HDL, Cholesterol, LDL, Lipoproteins, VLDL, Liver, Risk, Triglycerides, Cholesterol, VLDL, Dyslipidemias, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.